Why This Biosimilar Initiative In Rheumatology Is One To Watch

Originally published in Biosimilar Development by Anna Rose Welch, Editor Generally speaking, when it comes to fixing or advancing the U.S. healthcare system, it’s easier said than done. Look no further than the endless slew of proposed legislation that has, more often than not, been struck down in recent months. While in the EU, it’s …

Why This Biosimilar Initiative In Rheumatology Is One To Watch Read More »